Highlights
- Vaccine pass requirements are not mandatory in several of Taupō’s venues.
- Pacific Edge get a new CEO from Boston.
- Ryman Healthcare posts impressive HY22 performance.
Taupō’s District Council chief has announced a relaxation of My Vaccine Pass requirements across the district’s several venues and facilities from today onwards.
With the availability of children’s vaccines and high vaccination rates in the region, New Zealanders must learn to live with COVID-19 in the community, cites the District chief.
Some of the venues which no longer require vaccine passes for entry include Taupō Museum, AC Baths swimming pools, Great Lake Centre as well as Taupō District libraries.
However, Taupō Events Centre and function rooms continue to have vaccine passport requirements owing to capacity numbers, etc.
That said, let us look at the two popular NZX-listed healthcare stocks that can be considered.
Source: © 2022 Kalkine Media® data source- Refinitiv
Pacific Edge Limited (NZX:PEB; ASX:PEB)
Pacific Edge Limited is a leading name in the cancer diagnostic market, specialising in diagnostic and prognostic tests for better cancer detection and management. A few days ago, the Company had announced its new CEO, Dr Peter Meintjes, who has relocated from Boston to New Zealand and will work from the company’s Dunedin-based Head Office.
Do Must: PEB and GFL: 2 NZX penny stocks making strides today
Peter has vast experience in molecular diagnostics, especially in the US region.
At the time of writing, on 14 March, PEB was down by 2.22% at NZ$0.880.
Ryman Healthcare Limited (NZX:RYM)
Ryman Healthcare Limited is New Zealand’s famous operator of retirement villages. Sometime back, the Company released its HY22 report, highlighting an 8.5% growth in its unaudited underlying profit, amounting to NZ$95.9 million, owing to strong demand for its retirement living and aged care options.
Must Read: RYM, OCA- 2 NZX retirement village stocks amid COVID-19 surge in NZ
It has solid long-term growth plans and has commenced construction work across its new sites.
Moreover, in December 2021, RYM had distributed 8.8 cps as an interim dividend.
At the time of writing, on 14 March, RYM was trading flat at NZ$9.500.
Bottom Line
NZ boasts a robust healthcare sector, offering world-class products and services to its residents.
Be the First to Comment